Combination systemic therapy for advanced renal cell carcinoma

The Oncologist
Rowan E Miller, James M G Larkin

Abstract

Outcomes for patients with advanced renal cell carcinoma (RCC) have improved significantly in recent years with the development of novel noncytotoxic systemic therapies. The multitargeted kinase inhibitors sunitinib and sorafenib have been approved for the treatment of advanced RCC, and bevacizumab, a monoclonal anti-vascular endothelial growth factor antibody, has shown significant clinical activity, both as a single agent and in combination with interferon-alpha. The mammalian target of rapamycin inhibitors temsirolimus and everolimus have led to longer overall survival times in poor-risk patients in the first-line setting and longer progression-free survival times in kinase inhibitor refractory patients in the second-line setting, respectively. Despite these advances, almost all patients develop resistance to treatment and cure is rarely seen. There is therefore a need to overcome resistance, induce longer lasting remissions, and improve survival. A potential approach to this is to combine active agents, and the clinical data for combination therapy with novel targeted agents in advanced RCC are reviewed here.

References

Feb 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Charles L VogelMichael Press
Sep 21, 2002·Molecular and Cellular Biology·Christine C HudsonRobert T Abraham
Aug 2, 2003·The New England Journal of Medicine·James C YangSteven A Rosenberg
Oct 22, 2003·Journal of the American Society of Nephrology : JASN·William G Kaelin
Dec 24, 2003·The Cancer Journal·Diane D Davey
Sep 28, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·William G Kaelin
Jan 12, 2007·The New England Journal of Medicine·Robert J MotzerRobert A Figlin
Jan 12, 2007·The New England Journal of Medicine·Bernard EscudierUNKNOWN TARGET Study Group
Apr 4, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Alberto A ChiapporiPatrick J Creaven
May 2, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John D HainsworthUNKNOWN Minnie Pearl Cancer Research Network
Jun 1, 2007·The New England Journal of Medicine·Gary HudesUNKNOWN Global ARCC Trial
Aug 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jared A GollobJohn J Wright
Aug 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christopher W RyanUNKNOWN Southwest Oncology Group
Sep 19, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ronald M BukowskiDavid McDermott
Aug 2, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Brian I RiniDaniel J George
Oct 22, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Brian I RiniEric J Small
Feb 14, 2009·Clinical Genitourinary Cancer·Robert J MotzerRobert A Figlin
Feb 20, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Darren R FeldmanRobert J Motzer
Feb 20, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Akira InoueUNKNOWN North East Japan Gefitinib Study Group
May 19, 2009·The Journal of Urology·M P SablinB Escudier
Jun 3, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J MotzerRobert A Figlin

❮ Previous
Next ❯

Citations

May 6, 2011·Cancer Chemotherapy and Pharmacology·Ario TakeuchiSeiji Naito
May 24, 2013·Anti-cancer Drugs·Thomas J SemradPrimo N Lara
Sep 25, 2010·BMC Genomics·Cecelia A ShertzMaria E Cardenas
Jan 1, 2010·Drug, Healthcare and Patient Safety·Rohan ShahaniAnil Kapoor
Oct 6, 2010·Future Oncology·Deborah MukherjiLisa Pickering
Jul 1, 2011·Biometrics·Lorenzo TrippaPeter Müller
Jun 25, 2013·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Petra HeffeterWalter Berger
Sep 16, 2010·British Journal of Cancer·J M G LarkinM E Gore

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.